VITAMIN K3 DRUG EFFECTIVE AGAINST END-STAGE PROSTATE CANCER
Apatone[R] is a drug consisting of vitamin C and vitamin K3.
Vitamin K3 is being clinically tested as an agent to administer prior to chemotherapy to decrease the resistance tumor cells develop to chemo drugs.
In March 2008, the results of a study were published on prostate cancer patients who had failed standard therapy and were given the drug Apatone[R] at a dose that equaled 5,000 mg of vitamin C and 50 mg of vitamin K3.
An attempt to evaluate the effect of vitamin K3 using as an enhancer of anticancer agents.
The utility of vitamin K3 (menadione) against pancreatic cancer.